Seoul Pharma서울제약
018680 · KOSDAQ · ₩018680 · 서울제약
₩1,899▼ ₩1 (0.05%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 59.4% | 60.4% | 61.5% | 60.2% | 64.2% | 63.0% |
| Operating margin | −1.5% | −2.5% | 2.9% | 2.3% | 3.5% | −14.1% |
| Net margin | 3.4% | 1.4% | 3.2% | 6.7% | 1.7% | −23.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −2.1% | −2.7% | +2.1% | +4.8% | +23.7% | — |
| Operating income growth | +39.0% | −183.7% | +26.0% | −30.2% | +130.4% | — |
| Net income growth | +130.7% | −55.6% | −51.7% | +311.3% | +108.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 4.3% | 1.9% | 4.3% | 9.5% | 3.1% | −51.1% |
| Return on assets | 2.5% | 1.1% | 2.5% | 5.6% | 1.4% | −15.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 68.3% | 74.8% | 78.3% | 64.2% | 76.2% | 228.4% |
| Net debt to equity | −34.1% | 0.1% | 6.1% | 8.9% | 6.4% | 75.1% |
| Current ratio | 144.5% | 228.3% | 228.1% | 124.7% | 187.3% | 86.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Seoul Pharma / 서울제약 / 018680 / KRX:018680
Source: KRX statistical information